Glycoprotein isolate

Other Names

No alternative names.

Synopsis

Glycoprotein Isolate: A Comprehensive Reference

Terminological and Conceptual Scope

The term "glycoprotein isolate" as it appears in the dietary supplement marketplace is not a single, uniquely defined chemical substance but rather a category designation applied to purified or enriched fractions of naturally occurring glycoproteins derived from food or biological matrices. Glycoproteins are proteins that have carbohydrate chains covalently attached to amino acid side chains. They are ubiquitous in nature and serve roles in virtually every biological system. When the supplement industry uses the phrase "glycoprotein isolate," it most commonly refers to preparations derived from avian egg yolk — specifically the immunoglobulin Y (IgY) fraction, which is a glycoprotein in its own right. In some contexts the term also encompasses glycoprotein fractions isolated from bovine colostrum, mushrooms, or plant sources, depending on the manufacturer.

This article focuses primarily on the most extensively studied form used as a dietary supplement ingredient: egg yolk-derived IgY glycoprotein isolate, while also covering the broader biochemistry of dietary glycoproteins where scientific literature supports it. Claims that are not verifiable in peer-reviewed literature, government health agency documents, or official monographs are excluded.

Identity: Chemical Classification, Nomenclature, and Natural Sources

What Is a Glycoprotein?

Protein glycosylation — the covalent attachment of carbohydrate chains to proteins — is one of the most pervasive and functionally diverse post-translational modifications in eukaryotes. Among its various forms, N-linked and O-linked glycosylation stand out for their critical roles in protein folding, stability, cellular recognition, and signaling. Protein glycosylation is one of the most frequent post-translational modifications in eukaryotes; approximately one fifth of all proteins in protein structural databases are glycosylated.

There are two principal linkage types in glycoproteins of dietary relevance:

N-linked glycoproteins: N-linked glycosylation involves the en bloc transfer of a preassembled oligosaccharide onto the amide nitrogen of an Asn within the consensus sequence Asn–X–Ser/Thr (where X ≠ Pro) during nascent protein synthesis in the endoplasmic reticulum (ER). Human N-glycan is typically composed of N-acetyl-d-glucosamine (GlcNAc), d-mannose (Man), d-galactose (Gal), sialic acid, d-glucose (Glc), and l-fucose (Fuc) residues. N-glycan is classified into three groups: high-mannose type, hybrid type, and complex type.
O-linked glycoproteins: O-linked glycosylation attaches single sugar residues directly to the hydroxyl oxygen of Ser, Thr (and less commonly Tyr or Hyp) residues. The most common O-linked glycans are the mucin-type glycans, which contain an initial GalNAc residue. There are eight mucin-type core structures.

IgY: The Principal Supplement-Used Glycoprotein Isolate

The glycoprotein isolate most commonly sold as a dietary supplement ingredient is derived from the egg yolk of immunized or non-immunized hens and consists predominantly of Immunoglobulin Y (IgY), the avian equivalent of mammalian IgG. IgY is the major serum antibody of amphibians, reptiles and birds and shares a common ancestor with both mammalian IgG and IgE. IgY glycoprotein was first identified by Williams (1962) as gamma-globulin in a gamma-livetin fraction of yolk, which is produced in egg yolks (10–25 mg/ml) as well as in blood (5–6 mg/ml).

The main components in egg yolk are proteins and fats. Livetin is an important protein constituent in egg yolk, accounting for about 9.3% of the dry matter of the yolk, and it exists in the yolk in the form of α-, β-, and γ-yolk globulins. α-livetin's main component is albumin, the β-livetin's main component is the α-2-glycoprotein, and the γ-livetin main component is Immunoglobulin Y.

IgY is a glycoprotein because its heavy and light chains carry covalently attached carbohydrate moieties. IgY is structurally similar to mammalian immunoglobulin G (IgG) but does not bind human Fc receptors or complement system. This phylogenetic and structural distinction has important implications for its use as an oral supplement, as detailed below.

Common Commercial Preparations

Egg yolk powder / hyperimmune egg yolk (HEY): Dried whole egg yolk containing IgY fractions, used in clinical studies at doses of 10 g per day (see dosage section).
Purified IgY isolate: Stable IgY can be extracted in large quantities from egg yolk, a non-invasive preparation process that is more economical and ethical than serum-based antibody harvesting. Purified IgY can yield approximately 9.4 mg IgY per ml of egg yolk, as reported in one preparation study.
Encapsulated / microencapsulated IgY: Due to stability challenges in the gastrointestinal environment, researchers have developed encapsulated forms. If encapsulated, IgY preparations are particularly resistant to pH and digestive enzymes. Encapsulation of IgY with egg lecithin/cholesterol liposomes reduced the activity loss of IgY under gastric conditions.
Functional food fortifications: IgY has been incorporated into yogurt, infant formula, and drink powders in research settings. IgY has been formulated as a drink (IgY-containing egg powder dissolved in water) to be used as a swish-and-swallow passive immunization approach to neutralize pathogens in oropharyngeal cavities and the gastrointestinal tract.

Traditional and Historical Use

The concept of passive immunity by transferring specific antibodies from hen to chick via egg for chick protection was first demonstrated by Klemperer in 1893. This represents the earliest documented scientific recognition of egg yolk immunoglobulin's biological activity, though it was not exploited as a human dietary supplement at this time. It was in 1969 that Leslie and Clem coined the term "IgY" to refer to antibodies of poultry including those found in egg yolk.

Egg yolk has been consumed as a food for millennia across virtually all cultures, meaning humans have always ingested dietary glycoproteins including IgY incidentally. However, the deliberate use of egg-derived glycoprotein fractions as a supplement or passive immunotherapy in humans is an entirely modern, scientific-era development. There is no documented traditional ethnomedicinal practice that specifically identified and used isolated glycoprotein fractions from egg yolk for therapeutic purposes. The therapeutic concept originated from 19th and early 20th century immunology research.

The broader history of dietary glycoproteins as functional agents in human health is intertwined with the history of colostrum use. Bovine colostrum, which is rich in immunoglobulins and glycoproteins, has been used in traditional medicine in parts of Asia and Europe, particularly in early 20th century Scandinavia where colostrum-based preparations were given to newborns and sick individuals. However, the glycoprotein isolate as a defined, purified supplement is a product of 20th and 21st century biotechnology.

Key Constituents and Active Compounds

IgY: Molecular Structure

The heavy chain of IgY consists of a variable domain (VH) and four constant domains (CH1, CH2, CH3, and CH4). The two heavy chains are connected by disulfide bonds. The light chain has one variable domain (VL) and only one constant domain (CL). The Fragment antibody (Fab) domain binds to antigenic epitopes, and the Fragment crystallizable (Fc) domain of IgY has biological effector functions.

The main immunoglobulin present in avian blood (IgY) is transmitted to their offspring and accumulates in egg yolks, which enables non-invasive harvesting of high amounts of antibodies. Moreover, due to structural differences and phylogenetic distance, IgY is more suitable for certain diagnostic purposes than mammalian antibodies, since it does not react with certain components of the human immune system and displays greater avidity for mammalian conserved proteins.

N-Glycans in Dietary Protein Sources

N-glycans found within dietary glycoproteins or derived from the host may also serve as energy substrates for the adult microbiota, especially when fiber intake is low. N-glycoproteins ingested from diet or shed host epithelial cells are likely the primary sources of dietary N-glycans.

Key sugar moieties found in dietary glycoproteins include mannose, galactose, fucose, N-acetylglucosamine (GlcNAc), and sialic acid (N-acetylneuraminic acid). N-glycans that have complex, hybrid, or high mannose forms are linked to Asn via GlcNAc. GalNAc links O-glycans to Ser/Thr with a variety of core structures and extensions, most of which are sialylated and fucosylated.

Mechanisms of Action

The oligosaccharide moieties added to glycoproteins impact their structure and biological function by contributing to protein folding, stability, and transport to appropriate sub-cellular locations. Glycans also mediate cell–cell interactions, modulate signal transduction, and regulate molecular trafficking and endocytosis.

For the IgY glycoprotein isolate specifically, the proposed mechanisms of biological activity when taken orally are:

Passive mucosal immunity: IgY promotes specific immune responses during organismal infections mainly through two pathways. The first can directly adhere to pathogenic cell walls, destroying the integrity of pathogenic microorganisms and directly inhibiting the reproduction of pathogenic bacteria. The second method is to adhere to bacterial appendages (hairs/fimbriae), which prevents them from attaching to the intestinal mucosal epithelial cells.
Mucosal barrier reinforcement: IgY embedded in a double emulsion used as a dietary supplement attenuated LPS-induced damage to mouse small intestinal structures and protected the integrity of the jejunal mucosal barrier.
Non-complement-activating immunomodulation: Because IgY does not bind human Fc receptors or activate the complement cascade, its oral administration does not trigger systemic inflammatory responses. IgY itself does not activate the mammalian complement system or interact with rheumatoid factors.
Prebiotic-like glycan effects: The N-glycan chains on dietary glycoproteins can serve as substrates for beneficial gut bacteria. Among infants, N-glycans bound to human milk proteins can serve as important substrates for the gut microbe Bifidobacterium longum subsp. infantis, which has been shown to release N-glycans from human milk proteins in vivo, and access to available N-glycans can serve as an important fitness determinant for B. infantis. There is also evidence that N-glycans can serve as prebiotics.

Biochemical Roles of Glycosylation Relevant to Supplement Activity

In the ER, N-glycosylation directs the initial steps of protein folding and its quality control. N-glycosylation allows the newly synthesized glycoprotein to interact with the lectin-based chaperone system in the ER. In mammalian cells, calnexin, calreticulin, and related factors play a crucial role in facilitating the proper folding and oligomerization of numerous glycoproteins. They offer specialized quality control and chaperone functions tailored specifically for glycoproteins in the ER. O-glycosylation stabilizes the folded protein domain and promotes protein secretion.

Glycoproteins play critical roles in various biological processes, particularly in cell signaling, immune responses, and protein folding. Glycan structures preserve biomolecular information from the cell, with glycoproteins from different cell types and tissues displaying distinct patterns of glycosylation. Several decades of research have revealed that glycan structures also differ between normal physiology and disease.

Scientific Evidence by Area of Use

1. Gastrointestinal Health and Passive Mucosal Immunity

This is the most robustly studied application for egg yolk IgY glycoprotein isolate in humans.

Rotavirus Diarrhea

The most methodologically rigorous human clinical evidence for IgY supplementation involves its use against rotavirus-induced diarrhea in children. In a randomized, double-blind study, 79 children with known rotavirus diarrhea were assigned to receive either 10 g hyperimmune egg yolk (HEY) daily in four equally divided doses for 4 days (HEY group) or a similar preparation obtained from nonimmunized chicken (placebo group). In the HEY-treated group, there was significant reduction in stool output (in grams per kilogram per day; HEY vs. placebo; 87 ± 59 vs. 120 ± 75, P = 0.03), and significant reduction of ORS intake (in milliliters per kilogram per day) (HEY vs. placebo; 84 ± 46 vs. 122 ± 72, P = 0.008) on day 1 and clearance of virus on day 4 (HEY vs. placebo; 73% vs. 46%, P = 0.02). There was, however, no difference in diarrheal duration between the groups.

Treatment with HEY against four human rotavirus strains resulted in modest improvement of diarrhea associated with earlier clearance of rotavirus from stools. These results indicate an encouraging role of HEY in the treatment of rotavirus-induced diarrhea in children. Further studies are needed to optimize the dose and neutralization titer and thus improve the efficacy of egg yolk immunoglobulin IgY derived from immunized hens.

Evidence strength: Analysis of a number of rotavirus investigations involving animal and human clinical trials revealed that anti-rotavirus IgY significantly reduced the severity of clinical manifestation of diarrhea among IgY-treated subjects relative to a corresponding control or placebo group. The accumulated information as a whole depicts oral IgY to be a safe and efficacious option for treatment of rotavirus diarrhea in neonates. There is however a clear need for more randomized, placebo-controlled and double-blind trials with bigger sample size to further solidify and confirm claims of efficacy and safety in controlling diarrhea caused by rotavirus infection, especially among human infants with health issues such as low birth weights or compromised immunity.

Helicobacter pylori Infection

Multiple lines of evidence — from in vitro, animal, and early human studies — support the use of H. pylori-specific IgY as a dietary adjunct. The purity of purified IgY-Hp was 91.3%, with a yield of 9.4 mg of IgY per ml of egg yolk. The titer for IgY-Hp was 16 times higher than that for IgY in egg yolk from non-immunized hens, and IgY-Hp significantly inhibited the growth and urease activity of H. pylori in vitro. Bacterial adhesion on AGS cells was definitely reduced by preincubation of both H. pylori (108 CFU/ml) and 10 mg of IgY-Hp/ml.

In animal models, IgY-Hp decreased H. pylori-induced gastric mucosal injury as determined by the degree of lymphocyte and neutrophil infiltration. In this experimental model, H. pylori-associated gastritis could be successfully treated by orally administered IgY-Hp.

In humans, a notable clinical study was published examining IgY as an adjunct to antibiotic therapy. In this randomized, controlled study, 100 H. pylori-positive patients with previous H. pylori eradication treatment were included. All individuals received standard bismuth-containing quadruple therapy twice daily (5 mg ilaprazole, 100 mg doxycycline, 500 mg clarithromycin or 1 g amoxicillin or 100 mg furazolidone, and 220 mg colloidal bismuth tartrate) for 14 days and were randomized to receive either twice daily 7 g IgY-H. pylori or placebo. Another clinical study showed that oral anti-Hp mIgY for 2 weeks reduces urea breath test values and inhibits H. pylori activity.

Currently, IgY is used as an oral passive immunotherapy for preventing and controlling gastric and oral infections, with active applications in treating viral diarrhea and other gastrointestinal diseases.

Evidence strength: Most existing IgY–H. pylori-related studies have been conducted in animal studies, and fewer clinical studies exist. Evidence is preliminary to moderate; human RCT data are limited in sample size.

Enterotoxigenic E. coli (ETEC)

One study investigated the effects of IgY on growth, adhesion inhibitory activity, and morphology of enterotoxigenic Escherichia coli (ETEC) K88 in vitro, and evaluated the protective effects of IgY on intestinal health and immune response of mice infected with ETEC in vivo. Sixty pathogen-free C57BL/6J mice were divided into six treatment groups. Anti-ETEC IgY inhibited ETEC growth, reduced adherence of ETEC to intestinal epithelial cells, and damaged the morphology and integrity of the ETEC cell.

This body of work remains largely preclinical. No human RCT data specifically for IgY against ETEC were identified in the sources reviewed.

Gut Mucosal Barrier and Microbiome

Dietary glycans play a crucial role in human health by modulating gut microbiota, enhancing immune responses, and influencing metabolic processes. The prebiotic effects of glycans on gut microbiota composition and short-chain fatty acid (SCFA) production are highlighted, emphasizing their role in digestive health and gut barrier integrity. Additionally, glycans contribute to immune modulation by interacting with immune receptors, showcasing anti-inflammatory properties beneficial in autoimmune conditions.

Dietary glycans cause reproducible, dynamic, and differential alterations to the community structure of the human microbiome. Dietary glycans, widely used as food ingredients and not directly digested by humans, are of intense interest for their beneficial roles in human health through shaping the microbiome. This human evidence involves specific glycan types (fructooligosaccharides and polydextrose) assessed across 80 healthy volunteers, though evidence specifically for isolated egg yolk glycoprotein on the human microbiome remains less characterized.

The daily quantity and quality of plant glycans consumed by the human host have the potential to influence health. Members of the gut microbiota differ in ability to utilize different types of plant glycans. Dietary interventions with specific glycans could modulate the microbiota, counteracting ecological perturbations that disrupt the intricate relationships between microbiota and host (dysbiosis).

2. Respiratory Infections — Pseudomonas aeruginosa / Cystic Fibrosis

A phase 1 feasibility study evaluated oral administration of specific yolk antibodies (IgY) as a prophylactic or therapeutic option for Pseudomonas aeruginosa infections in patients with cystic fibrosis, with preliminary findings suggesting potential benefit, though this evidence is at an early phase and does not constitute proof of efficacy. IgY has demonstrated promising results in studies on antibacterial and antiviral infections. However, the pathways through which different pathogens infect the human body and the complex and diverse immune responses they trigger pose significant challenges. The precise and efficient exertion of its effects in the complex physiological environment of the human body requires further exploration.

3. Respiratory Viral Infections Including SARS-CoV-2

In the context of SARS-CoV-2, anti-spike protein IgY was investigated in a structured program including a Phase 1 human clinical trial. The experiments were conducted in four parts: production of immunogen (recombinant RBD), immunization of 12 SPF hens, IgY collection from egg yolks, and in vitro characterization of the IgY; Good Laboratory Practice (GLP)-blinded safety studies in rats treated intranasally twice daily for 28 days with a total of 16 mg/kg IgY or vehicle; a preliminary efficacy study of hamsters; and a placebo-controlled, double-blind phase 1 safety, tolerability, and pharmacokinetic study conducted in healthy humans using intranasal IgY or vehicle in single-ascending doses followed by multiple doses (three times daily every 4 hours) for 14 days.

IgY-based therapies like oral preparations, oral sprays, or nasal sprays could help in strengthening the barrier function of oral, nasal, and gastrointestinal mucosa. As the main entrance of viruses to the body, oral and nasal cavities are also high-risk sites for SARS-CoV-2 infection. A recent study found that IgY was maintained at detectable concentrations in the nasal and oral cavities for a matter of hours after administration.

Evidence strength: Phase 1 data only. No efficacy data in SARS-CoV-2-infected humans were identified. Evidence is preliminary.

4. Oral and Dental Health

IgY has been used in the treatment or prevention of dental caries, periodontitis and gingivitis, gastritis and gastric ulcer, oral thrush, and infant rotavirus diarrhea. However, most evidence in these areas remains from small studies or preclinical models. Human RCT data are sparse and have not been compiled into major systematic reviews or Cochrane analyses as of the sources reviewed.

Body Systems and Health Areas Associated with Glycoprotein Isolates

Gastrointestinal / Digestive System: The primary area of study. IgY glycoprotein isolate acts as a passive immunological agent within the gut lumen, inhibiting pathogen adhesion and supporting mucosal integrity. IgY is the predominant immunoglobulin isotype in chicken egg and as such acts as a major immunoglobulin fraction that confers passive gut immunity.
Immune System: Glycoproteins play critical roles in various biological processes, particularly in cell signaling, immune responses, and protein folding.
Gut Microbiome: Dietary glycans are a major driver of the human gut microbiota composition. The glycan chains on dietary glycoproteins can serve as substrates for specific beneficial bacterial species, particularly Bifidobacterium species. Oligosaccharides, in combination with glycoproteins and glycolipids, result mainly in a dominant abundance of Bifidobacterium species in breastfed infants.
Respiratory Mucosa: IgY delivered intranasally or orally (swish-and-swallow) has been studied for reinforcing mucosal immunity in the nasal and oral cavities, with early-phase clinical data as noted.
Oral Cavity / Dental: Several studies, as cited by IgY review articles, have evaluated anti-caries and anti-periodontal IgY preparations, with experimental results suggesting pathogen inhibition at oral mucosal surfaces.

Dosage Forms and Reported Dosages

The following dosages are reported in the specific scientific studies reviewed and should not be interpreted as general recommendations:

Rotavirus diarrhea in children: 10 g hyperimmune egg yolk (HEY) daily in four equally divided doses for 4 days was the protocol used in the published randomized trial.
H. pylori adjunct therapy: Patients were randomized to receive either twice daily 7 g IgY–H. pylori as an adjunct to standard bismuth quadruple antibiotic therapy for 14 days.
Anti-ETEC IgY in mouse models: 250 μL of high-dose (32 mg/mL), medium-dose (16 mg/mL), or low-dose (8 mg/mL) anti-ETEC IgY was used in the published preclinical study; no equivalent human dose has been established from these studies.
H. pylori in human volunteers: Seventeen asymptomatic volunteers diagnosed as H. pylori-positive by the 13C-urea breath test (UBT) were orally administered anti-HpU IgY for 4 weeks. The specific gram dosage was not available in the source accessed for this review.
Preparation yield: Purified IgY-Hp preparation with a purity of 91.3% yielded 9.4 mg of IgY per ml of egg yolk in one reported protocol.
Intranasal anti-SARS-CoV-2 IgY (Phase 1 humans): Single-ascending doses followed by multiple doses three times daily every 4 hours for 14 days were administered in the Phase 1 study; exact mg doses per administration were not reported in the summary data accessed.

It is important to note that IgY is proteinaceous and is therefore sensitive to heat, pH, and pepsin, meaning that the biologically active dose delivered to the gut may differ substantially from the administered dose depending on formulation.

Notable Safety Considerations and Known Interactions

Gastrointestinal Stability and Bioavailability Limitations

Oral administration of specific egg yolk immunoglobulin (IgY) is effective against a number of gastrointestinal pathogens. However, the activity of orally administered IgY is reduced rapidly, since IgY is sensitive to pepsin and low pH.

IgY is stable at temperatures ranging between 30°C and 70°C. The activity of IgY decreased by heating for 15 min at 70°C or higher, and IgY was denatured significantly when treated at temperatures higher than 75°C. This means that food preparations where glycoprotein isolate is subjected to high cooking temperatures will likely contain inactive protein.

IgY would lose their antigen-binding and cell agglutination activities at pH below 4.5 and would be degraded by pepsin. This is particularly relevant for oral administration, where stomach acid (pH typically 1.5–3.5) poses a substantial challenge to maintaining immunological activity. Several encapsulation strategies (liposomes, hydrogels, gum arabic coatings) have been researched to address this limitation.

Egg Allergy

There is no concern of allergic reactions to eggs arising from the final IgY products, as the final IgYs products do not contain allergenic albumin when properly purified. However, individuals with documented egg allergies should be aware that impure preparations of IgY may still contain residual egg proteins from the yolk matrix. This has been noted in the primary literature but has not been the subject of large-scale clinical safety assessment specific to supplement users.

Complement Non-Activation and Rheumatoid Factor Non-Reactivity

A documented structural advantage of IgY over mammalian immunoglobulins for oral use is that IgY is structurally similar to mammalian immunoglobulin G (IgG) but does not bind human Fc receptors or complement system. This means that even if small quantities of intact IgY are absorbed across the intestinal epithelium, they are unlikely to trigger the downstream inflammatory effector responses associated with complement activation.

pH Sensitivity in Newborns

Specific caution has been noted regarding neonatal use. In newborns, the gastric fluid has a pH close to neutral, but during the first days the pH rapidly decreases below pH 3, which will denature therapeutically administered IgY antibodies. This has practical implications for dosing timing and formulation in pediatric applications.

Bioavailability Concerns

Data from patent literature indicate that oral bioavailability of glycoprotein-type supplements is a significant concern. One study found that only 6% of ingested glycoprotein (glucosamine HCl) and 9% of glycoprotein (glucosamine NaCl) was detectable in serum after dosing. Previous radiomarker testing showed nearly 90% of the same glycoprotein was metabolized in the body, indicating a digestive net loss for the glycoprotein through metabolic processes of over 80%. These data suggest that for glycoprotein isolates intended to act systemically, oral bioavailability is substantially limited, though for agents intended to act locally within the gut lumen (such as IgY used as a passive mucosal immunotherapy), absorption into serum is not the relevant efficacy endpoint.

Absence of Known Drug Interactions

No specific pharmacokinetic drug interactions for egg yolk IgY glycoprotein isolate have been identified in the peer-reviewed sources reviewed. Its mechanism of action is local (gut lumen passive immunization) rather than systemic pharmacokinetic, making classical drug-drug interactions less of a concern. However, the absence of documented interactions should not be conflated with confirmed safety in the context of polypharmacy, as clinical data are insufficient to make such conclusions.

Antibiotic Resistance Context

IgY has been specifically proposed as a supplement adjunct in the context of growing antibiotic resistance. The increasing antibiotic resistance is the main issue causing Helicobacter pylori eradication failure. As a nutritional supplement, Egg Yolk Antibody (IgY) provides a new approach for H. pylori infection rescue therapy. This framing positions IgY not as a drug replacement but as a co-intervention; the use of any supplement as a substitute for prescribed antibiotic therapy for confirmed pathogen infections falls outside the scope of the current evidence base.

Summary of Evidence Strength

Rotavirus diarrhea (children): At least one well-designed, randomized, placebo-controlled, double-blind trial (n=79) showing modest benefit; further replication needed.
H. pylori: Promising in vitro and animal data; limited human clinical evidence; one RCT published as of the reviewed sources, using IgY as an adjunct.
Pseudomonas / cystic fibrosis: Phase 1 feasibility only; insufficient evidence for efficacy conclusions.
Respiratory viral infections (SARS-CoV-2): Phase 1 safety/tolerability data only; no human efficacy data.
Gut microbiome modulation: Plausible and supported by mechanistic evidence for dietary N-glycans broadly; specific human intervention data for egg yolk IgY glycoprotein isolate on the microbiome are limited.
Metabolic/systemic effects: No verified high-quality human evidence for egg yolk glycoprotein isolate specifically in metabolic or systemic disease areas, as of the sources reviewed.

References

Health Conditions

Health conditions that Glycoprotein isolate may help support.

No conditions available.

Body Systems

Body systems that Glycoprotein isolate may help support.

No body systems available.